bioRxiv Science⌕ Search

Biology subjects

Estave, P. M.

Publications and source records attributed to Estave, P. M..

2 recordsLinked to original sources

Kappa opioid receptors regulate cocaine effects on nucleus accumbens dopamine through phosphorylation of dopamine transporter at the threonine 53 site

Chronic cocaine exposure leads to tolerance of the dopamine transporter (DAT) to cocaine and heightened kappa opioid receptor (KOR)-induced inhibition of dopamine (DA) release in the nucleus accumbens (NAc). KORs on presynaptic DA terminals inhibit DA release and modulate DAT function, but whether KOR signaling causes DAT tolerance is unknown. We demonstrate that rats self-administering cocaine escalate their intake, and the KOR antagonist norbinaltorphimine (nBNI) blunts this escalation. We employed fast-scan cyclic voltammetry (FSCV) in acute brain slices containing the NAc core from these rats and found that the cocaine exposure paradigm resulted in tolerance of the DAT to cocaine, an effect absent in animals pre-treated with nBNI. In drug-naive mice, either superfusion of the KOR agonist U50,488 or a single in vivo injection of U69,593 inhibited DA release and reduced cocaine-induced inhibition of DA reuptake, reproducing the tolerance phenotype without any drug history. We replicated this finding in the NAc of rats, and with the uptake inhibitor nomifensine in rhesus macaques, indicating conservation across rodents and non-human primates. As KOR activation results in phosphorylation of the threonine-53 site on the DAT, we tested whether this is required for the KOR-mediated DAT tolerance to cocaine. We show that a mouse line with a phosphorylation-insensitive alanine-53 mutation of the DAT has enhanced DA release and uptake. Remarkably, KOR agonism no longer mediated DAT tolerance to cocaine in these mice, demonstrating the dependence of this effect on the threonine-53 site and highlighting a KOR-driven mechanism underlying cocaine tolerance at the DAT.

neuroscience↗

Nicotine Modifies Responding for Cocaine in a Concurrent Rodent Self-administration Model

Prevailing preclinical models of cocaine use have not resulted in an FDA-approved treatment for cocaine use disorder, potentially due to a focus on cocaine use in isolation, which may not translate well to polysubstance use in clinical populations. Clinically, nicotine has been shown to increase cocaines potency and reinforcing efficacy, but some preclinical studies suggest that non-contingent nicotine exposure is not sufficient to alter cocaine self-administration in rats; therefore, this experiment examined if the addition of nicotine to the cocaine solution would alter self-administration behavior. Male Sprague Dawley rats (N=7) were trained to self-administer cocaine (0.75mg/kg/inf), and tested on a long access, fixed ratio 1 schedule of reinforcement (6 hour sessions, unlimited inf, 5 days), for cocaine alone (0.75mg/kg/inf), followed by cocaine and nicotine (0.75mg/kg/inf cocaine+0.03mg/kg/inf nicotine). Finally, rats responded on a progressive ratio schedule for varied doses of cocaine with and without concurrent nicotine at a consistent dose (1.5, 0.75, 0.375, 0.19mg/kg/inf cocaine{+/-} 0.03mg/kg/inf nicotine). Unexpectedly, under long access conditions, rats self-administering cocaine and nicotine responded less than for cocaine alone, and did not escalate responding. However, under progressive ratio conditions, responding for cocaine and nicotine was greater than responding for cocaine alone across low and moderate cocaine doses, and decreased at high cocaine doses, indicating a leftward shift in the dose response curve. Together, these data highlight the importance of evaluating multiple outcome measures in nicotine + cocaine paradigms, and suggest that concurrent self-administration of cocaine and nicotine results in greater motivated responding than for cocaine alone.

neuroscience↗